title: In vitro donor-specific hyporesponsiveness and T cell subsets in renal allograft recipients.
abstract: In order to assess the immune mechanisms triggered by an immunosuppressive regimen consisting of prophylactic antilymphocyte globulin plus low-dose cyclosporine A and steroids, we studied the short-term evolution of both, anti donor in vitro alloresponse and peripheral blood T cell subsets in 21 recipients of a cadaveric kidney allograft. Spleen cells from cadaveric donors and peripheral blood lymphocytes from the respective recipients pretransplant (pre-Tx), at three and six months posttransplant (post-Tx) were obtained to perform one-way mixed lymphocyte cultures and flow cytometry analysis of lymphocyte subsets. The results indicated the development of donor-specific mixed lymphocyte culture (MLC) hyporesponsiveness as early as three months post-Tx, paralleled by a decrease in CD4+CD29+ helper-inducer cells and by an increase in CD8+CD45RA+ suppressor lymphocytes in peripheral blood. These changes were reflected in a very good clinical outcome of the patients. The present results further suggest that suppression of the immune system just before transplantation is a suitable method to induce early specific hyporesponsiveness to the allograft.
authors.affiliation: Immunology Service, Ciutat Sanitària Universit aria de Bellvitge, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Bas
authors.forename: M
authors.initials: M
authors.lastname: Mestre
authors.forename: J M
authors.initials: JM
authors.lastname: Griñó
authors.forename: E
authors.initials: E
authors.lastname: Massip
authors.forename: A M
authors.initials: AM
authors.lastname: Castelao
authors.forename: A
authors.initials: A
authors.lastname: Romeu
authors.forename: L
authors.initials: L
authors.lastname: González
authors.forename: A
authors.initials: A
authors.lastname: Valls
authors.forename: E
authors.initials: E
authors.lastname: Buendía
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006648:Histocompatibility; D006801:Humans; D007108:Immune Tolerance; D016030:Kidney Transplantation / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D011292:Premedication; D016176:T-Lymphocyte Subsets; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D016572:Cyclosporine; D011241:Prednisone